CSL 311Alternative Names: CSL311
Latest Information Update: 05 May 2016
At a glance
- Originator CSL
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists; Interleukin 3 receptor antagonists; Interleukin 5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Allergic asthma
Most Recent Events
- 01 Nov 2012 Phase-II clinical trials in Allergic asthma in Canada (Parenteral) (NCT01759849)